Publications by authors named "Jason D Lickliter"

Claim this Profile
A
A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers.
Thomas R Moench, Lakshmi Botta, Brian Farrer, Jason D Lickliter, Hyunah Kang

EBioMedicine· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study.
Nishit B Modi, Richard Shames, Jason D Lickliter, Suneel Gupta

Eur J Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme.
Jason D Lickliter, Jeremy Ruben, Ganessan Kichenadasse, Ross Jennens, Cecelia Gzell

Cancer Res Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum for Lickliter et al., "Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects".
Jason D Lickliter, Kenneth Lawrence, John O'Donnell, Robin Isaacs

Antimicrob Agents Chemother· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cathepsin-Targeted Quenched Activity-Based Probe Facilitates Enhanced Detection of Human Tumors during Resection.
Gregory T Kennedy, David E Holt, Feredun S Azari, Elizabeth Bernstein, Bilal Nadeem, Jason D Lickliter

Clin Cancer Res· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Jason D Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K Gan, Ganessan Kichenadasse

Br J Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases.
Michael C Chen, Christopher C Korth, Mark D Harnett, Eric Elenko, Jason D Lickliter

Clin Pharmacol Drug Dev· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Jason D Lickliter, Mark Voskoboynik, Linda Mileshkin, Hui K Gan, Ganessan Kichenadasse

Br J Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular responses at the application site of a high-density microarray patch delivering an influenza vaccine in a randomized, controlled phase I clinical trial.
Alexandra C I Depelsenaire, Katey Witham, Margaret Veitch, James W Wells, Christopher D Anderson, Jason D Lickliter

PLoS One· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
Hui K Gan, Michael Millward, Mathilde Jalving, Ignacio Garrido-Laguna, Jason D Lickliter

Oncologist· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.
Jing Yang, Jason D Lickliter, Jan L Hillson, Gary D Means, Russell J Sanderson

Clin Transl Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study.
Joshua Osowicki, Kristy I Azzopardi, Loraine Fabri, Hannah R Frost, Tania Rivera-Hernandez, Jason D Lickliter

Lancet Microbe· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers.
Adele Hosseini, Andrew J McLachlan, Jason D Lickliter

Br J Clin Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin (EU) in healthy adult males.
Jason D Lickliter, Rakesh Naranbhai Dadhania, Ravi Kumar Trivedi, S R Naveen Kumar, Pramod Kumar Reddy

Indian J Med Res· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.
Jason D Lickliter, Hui K Gan, Mark Voskoboynik, Surein Arulananda, Bo Gao

Drug Des Devel Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Cheryl Keech, Gary Albert, Iksung Cho, Andreana Robertson, Patricia Reed, Jason D Lickliter

N Engl J Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects.
Jason D Lickliter, Kenneth Lawrence, John O'Donnell, Robin Isaacs

Antimicrob Agents Chemother· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults.
Stephen B Shrewsbury, Jasna Hocevar-Trnka, Kelsey H Satterly, Karen L Craig, Jason D Lickliter

J Clin Psychiatry· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Angus H Forster, Katey Witham, Alexandra C I Depelsenaire, Margaret Veitch, James W Wells, Jason D Lickliter

PLoS Med· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Jun Keng Khoo, A Bruce Montgomery, Kelly L Otto, Mark Surber, Jessica Faggian, Jason D Lickliter

J Aerosol Med Pulm Drug Deliv· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study.
Hidenori Kato, Paul de Souza, Sang-We Kim, Jason D Lickliter, Yoichi Naito

Target Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46).
Benedict J Panizza, Paul de Souza, Adam Cooper, Aflah Roohullah, Christos S Karapetis, Jason D Lickliter

EBioMedicine· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers.
Malek Okour, Angela Gress, Xinyi Zhu, David Rieman, Jason D Lickliter

Clin Pharmacol Drug Dev· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Hui K Gan, Michael Millward, Ye Hua, Chuan Qi, Yang Sai, Jason D Lickliter

Clin Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.
Michael Grundman, Roger Morgan, Jason D Lickliter, Lon S Schneider, Steven DeKosky

Alzheimers Dement (N Y)· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis